Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem/Cilastatin in Subjects With Imipenem-Resistant Bacterial Infection

Next Previous
Search
Trial Profile

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem/Cilastatin in Subjects With Imipenem-Resistant Bacterial Infection

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilastatin/imipenem/relebactam (Primary) ; Colistimethate sodium; Imipenem/cilastatin
  • Indications Bacterial infections; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RESTORE-IMI 1
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 09 Nov 2022 Results assessing the cost effectiveness (model includes data from the RESTORE-IMI-1 trial) of Imipenem/cilastatin/relebactam in gram negative infections in Greece, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 20 May 2021 A US single payer model with a lifetime horizon comprising a decision-tree depicting initial hospitalization and a Markov model projecting long-term health and economic impact was developed using RESTORE-IMI 1 and US surveillance data, results presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 24 Feb 2020 Results of comparison of treatment outcomes between analysis populations in the RESTORE-IMI 1 Phase 3 trial of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in patients with imipenem-nonsusceptible bacterial infections has been published in the Antimicrobial Agents and Chemotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top